IMJUDO

This brand name is authorized in Austria, Estonia, France, Croatia, Ireland, Italy, Japan, Lithuania, Romania, United Kingdom, United States

Active ingredients

The drug IMJUDO contains one active pharmaceutical ingredient (API):

1 Tremelimumab UNII QEN1X95CIX - TREMELIMUMAB

Tremelimumab is a selective, fully human IgG2 antibody that blocks CTLA-4 interaction with CD80 and CD86, thus enhancing T-cell activation and proliferation, resulting in increased T-cell diversity and enhanced antitumour activity. Cytotoxic T lymphocyte-associated antigen (CTLA-4) is primarily expressed on the surface of T lymphocytes. Read about Tremelimumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
IMJUDO Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FX20		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX20

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3038565, 3038576
Country: FR	Base de données publique des médicaments	Identifier(s): 68577115
Country: IT	Agenzia del Farmaco	Identifier(s): 050595014, 050595026
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291465A1020, 4291465A2026
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1096578, 1096579
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W69596001, W69596002
Country: US	FDA, National Drug Code	Identifier(s): 0310-4505, 0310-4535